Compounded tirzepatide is dispensed by U.S.-licensed 503A compounding pharmacies and 503B FDA-registered outsourcing facilities. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®. It is generally significantly less expensive than the brand names.
Compounded tirzepatide is dispensed by U.S.-licensed 503A compounding pharmacies and 503B FDA-registered outsourcing facilities. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®. It is generally significantly less expensive than the brand names.
Manufacturer / source: Various compounding pharmacies
For tirzepatide forms head-to-head, see comparison page. For trial data, see clinical research.
Compounded tirzepatide is a non-FDA-approved formulation of the tirzepatide active ingredient, prepared by licensed compounding pharmacies. It is not the same product as Mounjaro or Zepbound and is not subject to the same manufacturing oversight, though licensed 503A and 503B facilities operate under defined state and federal pharmacy regulations.
Compounded tirzepatide aims to deliver the same dual GIP/GLP-1 receptor agonist active ingredient as the brand products. However, the inactive ingredients (excipients, preservatives, buffers), concentration, and final formulation differ from brand-name vials and pens. Some compounded formulations include additives such as B12, glycine, or niacinamide; the clinical rationale for these additions is debated.
Tirzepatide was on the FDA drug shortage list from late 2022 through October 2024. During that window, 503A and 503B pharmacies could lawfully compound tirzepatide under FDCA Sections 503A and 503B respectively. After the FDA declared the shortage resolved in late 2024, mass 503B compounding of tirzepatide ended; 503A pharmacies continue to compound patient-specific formulations on a case-by-case basis, often relying on personalization (such as dose adjustment or excipient differences) to qualify under Section 503A. Post-April 2026 enforcement actions have further narrowed the compounded landscape.
503B outsourcing facilities are registered with the FDA, inspected for current Good Manufacturing Practice (cGMP) compliance, and may produce batches without patient-specific prescriptions. 503A pharmacies are state-licensed traditional compounders that require a patient-specific prescription and follow USP <797> (sterile preparation) and USP <800> (hazardous drug) standards. Both have produced safe tirzepatide formulations when operating in compliance; both have also been the subject of FDA warning letters and adverse event reports when standards lapsed.
Compounded tirzepatide is most commonly supplied as multi-dose vials in concentrations such as 5 mg/mL, 10 mg/mL, or 15 mg/mL, with patients self-administering measured doses by insulin syringe. This differs from brand-name pens and increases the importance of pharmacy labeling clarity, patient education, and verified dosing.
Compounded tirzepatide typically prices in the $159–$399 per month range depending on provider, dose, and pharmacy. Pricing transparency varies widely — some providers publish flat rates inclusive of all titration doses, while others charge per-dose and escalate costs through the titration period.
Compounded tirzepatide can be lawfully prepared by appropriately licensed 503A pharmacies for individual patients under specific regulatory conditions. Mass 503B production largely ended after the FDA resolved the shortage in 2024. The regulatory environment continues to evolve, and patients should verify their compounding pharmacy's licensure and current standing.
There are no head-to-head trials comparing compounded tirzepatide to brand-name Zepbound. Some patients report comparable outcomes; others have reported issues with potency variability, injection-site reactions, or supply interruption. Clinical equivalence cannot be assumed.
Check the pharmacy's license through its state board of pharmacy, look for accreditation (PCAB for compounding, ACHC), confirm 503A or 503B designation, and check the FDA's published 503B Registered Outsourcing Facilities list. Telehealth providers should disclose which pharmacy or pharmacies they use.
Risks include contamination from sterile-preparation errors, dosing errors from concentration misinterpretation, variable potency between batches, and the absence of FDA pre-market review of the specific formulation. Provider oversight and pharmacy quality matter substantially.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000